Melanie K Spriggs

This inventor holds 33 USPTO granted patents and 1 published patent application, primarily in Immunology Research. Top assignees: Immunex Corporation, Other. Active years: 1996-2008.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Melanie K Spriggs. Retrieved from https://idiyas.com/inventor/melanie-k-spriggs

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 33 (Patent Applications = 1)

% Patents Active = 90.9

Average Co-Inventor Count = 3.3

ph-index = 17

Forward Citations = 659(Granted Patents)

Company Filing History:

32 out of 451

Immunex Corporation

patents

1 out of 834,453

Other

patents

Years Active: 1996-2008

Loading Chart...

Areas of Expertise:

IL-17 Receptor

CD40 Ligand

Antibodies

Autoimmune Disease

Asthma Treatment

Hybridomas

Vaccine Response

Cytokines

Inflammatory Response

Semaphorin Polypeptides

MHC Class II

Graft Rejection

33 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 7432237 - Methods of treating asthma by administering interleukin-17 receptor (2008-10-07),

2. 7405270 - CD40-Ligand lacking native-pattern glycosylation (2008-07-29),

3. 7309489 - Mouse CD40 ligand-specific antibodies and hybridomas (2007-12-18),

4. 7273843 - Methods of treating allergy by administering interleukin-17 receptor (2007-09-25),

5. 7214497 - Viral encoded semaphorin protein receptor DNA and polypeptides (2007-05-08),

6. 6680057 - Methods of treating autoimmune disease by administering interleukin-17 receptor (2004-01-20),

7. 6670135 - Semaphorin polypeptides (2003-12-30),

8. 6613320 - Defective CD4+T-cells that express active CD40-L (2003-09-02),

9. 6562949 - Antibodies to viral encoded semaphorin protein receptor polypeptides (2003-05-13),

10. 6410711 - DNA encoding CD40 ligand, a cytokine that binds CD40 (2002-06-25),

11. 6391637 - Use of CD40 ligand, a cytokine that binds CD40, to stimulate hybridoma cells (2002-05-21),

12. 6290972 - Method of augmenting a vaccine response by administering CD40 ligand (2001-09-18),

13. 6264951 - Methods of inhibiting CD40L binding to CD40 with soluble monomeric CD40L (2001-07-24),

14. 6197525 - Assay kits for detection and methods of inhibiting IL-17 binding (2001-03-06),

15. 6191104 - Methods of treating graft rejection with the IL-17 receptor (2001-02-20),

Title: **Melanie K. Spriggs: A Pioneer in Asthma Treatment Innovations**

Introduction

Melanie K. Spriggs, based in Seattle, WA, stands out as a prominent inventor in the field of immunology and respiratory health. With an impressive portfolio of 33 patents, her contributions have significantly advanced the understanding and treatment of asthma through innovative molecular techniques.

Latest Patents

Among Melanie's latest patents are groundbreaking methods for treating asthma by administering interleukin-17 receptor. This innovation presents isolated receptors for IL-17 and DNA encoding such receptors, which can be utilized to regulate immune responses effectively. Another notable patent involves a CD40-Ligand that lacks native-pattern glycosylation, providing polypeptides and DNA sequences that bind to the extracellular binding region of a CD40 receptor. These developments showcase Melanie's commitment to enhancing therapeutic options for patients suffering from asthma and other related conditions.

Career Highlights

Throughout her career, Melanie K. Spriggs has made remarkable strides, particularly during her tenure at Immunex Corporation. Her work has not only led to numerous patents but has also established her as a key figure in the biotechnology sector, focusing on immunological advancements.

Collaborations

Melanie has collaborated with notable professionals in her field, including William Christian Fanslow, III and Richard Jeffrey Armitage. These partnerships have been instrumental in propelling her research forward and driving innovations that benefit public health.

Conclusion

Melanie K. Spriggs exemplifies the spirit of innovation in medical science, particularly in the realm of asthma treatment. Her extensive patent portfolio and significant collaborations highlight her dedication to discovering novel therapies that can improve patient outcomes. As she continues her work, Melanie remains a vital asset to the scientific community and an inspiration to aspiring inventors.

Profile summary based on public USPTO records.

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

1 patent pending: